Omeros Plans To Close International Free-Drug Enrollment As U.S. Demand Grows
Current patients will receive enough Yartemlea to finish treatment as the company pursues reimbursed access abroad.
Omeros, a biotechnology company developing protein and small-molecule drugs, plans to stop enrolling new patients in its international free-drug program for Yartemlea. Dr. Gregory A. Demopulos, Omeros’ chairman and chief executive officer, said on Monday’s earnings call that increasing U.S. commercial demand prompted the decision.
Paid Access After Europe's Rejection
The planned cutoff would change an arrangement under which Omeros has supplied medicine without charge in Europe and other international regions for 10 years. Patients already receiving Yartemlea through that compassionate-use program will get enough medicine to finish their treatment.
Omeros is pursuing fully reimbursed named-patient programs — access arranged for individual patients — in parts of Europe and other regions. Demopulos said its regulatory work now focuses outside the European Union, seeking near-term approvals from authorities able to build on the FDA’s approval.
The European Medicines Agency’s advisory committee reaffirmed its rejection of the drug in October, after a negative opinion in June, according to Omeros’ results release. On the call, Demopulos described the committee’s process and decision as “from our perspective, misguided.”
Some Free Courses Exceeded A Year
A question from a Needham analyst about treatment duration exposed another feature of free access: some patients, mostly children, stayed on the medicine beyond a year.
Demopulos said their physicians kept treating them because they feared relapse, even when the drug was working. He said supplying medicine free through expanded access likely played a substantial role in allowing those lengthy courses.
That experience contrasts with the average of eight to 10 vials per treatment course in Omeros’ study and expanded-access program. Demopulos said the company was seeing more twice-weekly treatment early in a course, alongside increasing outpatient use.
U.S. Sales Fund The Business
Yartemlea treats TA-TMA, a potentially fatal complication of stem cell transplantation, in patients aged two and older. It is Omeros’ one commercial product, sold through the company’s own U.S. field force working with transplant centers. FDA approval came in December 2025, and Demopulos said the launch began in late January.
Third-quarter net revenue rose 26% to $35.9 million from $28.5 million in the second quarter. Gross revenue reached $41.8 million, up 30% from the prior quarter, and operating cash flow was positive at $13.3 million.
The U.S. customer base expanded to 109 accounts that had ordered Yartemlea by September 30, from 73 at June 30, a 49% increase. Demopulos said revenue growth has continued into the fourth quarter.
The international shift leaves existing free-access patients supplied through treatment completion, while Omeros seeks paid routes for patients abroad.
Sources
- Omeros results release (Form 8-K, EX-99.1) — SEC EDGAR
- ex_1011405.htm — sec.gov
- Omeros Corporation Reports Third Quarter 2026 Financial Results – Company Announcement - FT.com — Financial Times
- Omeros: Q3 Earnings Snapshot – WTOP News — wtop.com
- Omeros: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Omeros: Q3 Earnings Snapshot | king5.com — Associated Press